Cytokinetics (CYTK) director awarded shares and 4,301 stock options

Rhea-AI Filing Summary

Harrington Robert Arthur reported acquisition or exercise transactions in this Form 4 filing.

Cytokinetics director Robert Arthur Harrington received equity compensation in the form of common stock and stock options. He was granted 2,851 shares of common stock and now holds 21,781 shares directly.

He was also granted 4,301 non-qualified stock options exercisable at $77.15 per share, expiring on May 26, 2036, linked to 4,301 shares of common stock.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Harrington Robert Arthur

Role null

Type	Security	Shares	Price	Value
Grant/Award	Non-Qualified Stock Option (Right to Buy)	4,301	$0.00	--
Grant/Award	Common Stock	2,851	$0.00	--

Holdings After Transaction: Non-Qualified Stock Option (Right to Buy) — 4,301 shares (Direct, null); Common Stock — 21,781 shares (Direct, null)

Footnotes (1)

Key Figures

Common stock granted: 2,851 shares Common shares held after award: 21,781 shares Options granted: 4,301 options +3 more

6 metrics

Common stock granted 2,851 shares Equity award on May 27, 2026

Common shares held after award 21,781 shares Direct holdings after transactions

Options granted 4,301 options Non-qualified stock option grant

Option exercise price $77.15 per share Conversion or exercise price

Option exercisability date June 27, 2026 Exercise start date for options

Option expiration date May 26, 2036 Expiry of non-qualified stock options

Key Terms

Non-Qualified Stock Option (Right to Buy), transaction code A, grant/award acquisition

3 terms

Non-Qualified Stock Option (Right to Buy) financial

"Non-Qualified Stock Option (Right to Buy)"

transaction code A financial

"transaction_code": "A""

grant/award acquisition financial

"transaction_action": "grant/award acquisition""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Harrington Robert Arthur

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/27/2026		A		2,851	A	$0	21,781	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (Right to Buy)	$77.15	05/27/2026		A		4,301		06/27/2026	05/26/2036	Common Stock	4,301	$0	4,301	D

Explanation of Responses:

	/s/ John Faurescu, attorney-in-fact for Dr. Harrington	05/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did CYTK director Robert Harrington report on this Form 4?

Director Robert Harrington reported equity compensation awards, not open-market trades. He received 2,851 shares of Cytokinetics common stock and 4,301 non-qualified stock options, all recorded as acquisitions under transaction code A for grant or award.

How many CYTK common shares does Robert Harrington hold after these awards?

After the stock grant, Robert Harrington directly holds 21,781 shares of Cytokinetics common stock. This figure reflects his position following receipt of 2,851 new shares awarded as compensation on May 27, 2026, according to the Form 4 filing details.

What are the terms of Robert Harrington’s new Cytokinetics stock options?

Harrington received 4,301 non-qualified stock options with an exercise price of $77.15 per share. These options relate to 4,301 underlying common shares, become exercisable starting June 27, 2026, and expire on May 26, 2036, as shown in the derivative transaction entry.

Was Robert Harrington’s CYTK Form 4 a buy or sell of shares?

The Form 4 reflects acquisitions through grants, not market buys or sales. Both reported transactions use code A, indicating grant or award acquisitions of common stock and options, with no open-market purchase or sale activity disclosed in this filing.

Does the CYTK Form 4 show any derivative exercises by Robert Harrington?

The Form 4 does not report any option exercises. It shows one derivative transaction: a grant of 4,301 non-qualified stock options. Transaction summaries list zero exercises, indicating no conversion of options into common stock during this reporting period.